Brief: Advaxis Announces Agreement With Columbia University Irving Medical Center To Fund Phase 1 Study Of Adxs-504 For The Treatment Of Early Prostate Cancer
05/04/2021 13:21
April 5 (Reuters) - Advaxis Inc ADXS.O :
* ADVAXIS ANNOUNCES AGREEMENT WITH COLUMBIA UNIVERSITY
IRVING
MEDICAL CENTER TO FUND PHASE 1 STUDY OF ADXS-504 FOR THE
TREATMENT OF EARLY PROSTATE CANCER
* ADVAXIS INC - STUDY, EXPECTED TO BEGIN IN Q2 2021, WILL BE
FIRST
CLINICAL EVALUATION OF ADXS-504
Source text for Eikon: ID:nGNX4NjHSd
Further company coverage: ADXS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ayala Pharmaceuticals
See all newsBrief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals
Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors